Cardiogen
A synthetic Khavinson tetrapeptide (Ala-Glu-Asp-Arg) researched as a cardiac-tissue-targeted bioregulator for myocardial function and cardiovascular aging.
Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg, AEDR) developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as the cardiac-specific member of the Khavinson short-peptide bioregulator family. It is positioned as a 'myocardial bioregulator' intended to support cardiomyocyte function, vascular endothelium, and cardiac tissue resilience in age-related cardiovascular decline, post-infarction recovery, and chronic heart failure. Cardiogen is the synthetic defined-sequence counterpart to the bovine cardiac tissue extract Chelohart. Evidence is limited to preclinical rodent and in vitro cardiomyocyte work plus small uncontrolled Russian observational series; no placebo-controlled human trials exist and it is not approved by any major Western regulator.
Class
Synthetic tetrapeptide (Khavinson cardiac bioregulator)
Half-life
Not formally characterized; small peptide rapidly hydrolyzed to constituent amino acids
Routes
Oral capsule, Sublingual, Subcutaneous injection
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Cardiovascular tissue support
Proposed to support cardiomyocyte function and vascular endothelium in age-related cardiovascular decline. Evidence is preclinical: in vitro cardiomyocyte culture and rodent studies from the Khavinson group, with no controlled human trials.
Cardiac muscle repair and resilience
Positioned for cardiac tissue resilience in post-infarction recovery and chronic heart failure contexts. Russian rodent cardiac-injury models report protective effects; independent replication is limited.
Improved heart function markers
Uncontrolled observational series in elderly cardiovascular patients report subjective improvement and modest echocardiographic changes after oral cycles. No hard-endpoint (MACE, cardiovascular death, HF hospitalization) data exist.
Ischemic adaptation and cardioprotection
Preclinical rodent ischemia-reperfusion models have reported cardioprotective effects and changes in cardiac gene-expression markers. Mechanism remains a hypothesis rather than a measured pharmacological action.
Anti-aging effects on cardiac tissue
Within the Khavinson framework Cardiogen is proposed to up-regulate cardiomyocyte-survival, mitochondrial-biogenesis, and regeneration programs in aging hearts. This tissue-specific targeting is asserted but not validated by modern transcriptomic or structural methods.
Mechanism
How it works
Cardiogen's proposed mechanism follows the standard Khavinson short-peptide bioregulator model applied to cardiac tissue, described in three stages: absorption and tissue distribution, nuclear import, and sequence-selective chromatin modulation. At roughly 488 daltons (H-Ala-Glu-Asp-Arg-OH), the peptide is small, polar, and flexible enough to be described as crossing phospholipid bilayers passively. Khavinson tritiated-peptide biodistribution work in rodents reports tissue uptake across heart, liver, brain, thymus, and kidney within minutes of intraperitoneal or oral dosing, though those radiolabel studies do not distinguish intact peptide from hydrolysis products.
The framework proposes that AEDR diffuses through the cardiomyocyte sarcolemma, T-tubule membrane system, and nuclear envelope without receptor-mediated transport, then makes sequence-selective contacts with exposed DNA regions and histone tails in chromatin carrying cardiac survival and regeneration genes. Khavinson's group suggests preferential activation of silenced chromatin regions governing mitochondrial biogenesis (PGC-1 family), survival factors (BCL-2 / Bax ratio), contractile proteins (myosin heavy chains), calcium-handling proteins (SERCA2a, ryanodine receptor), and anti-fibrotic programs. The molecular-validation standards of modern chromatin biology — co-crystal structures, ChIP-seq on tagged peptide, ATAC-seq, CUT&RUN — have not been published for AEDR.
A more conservative interpretation treats Cardiogen as an amino-acid source delivering alanine, glutamate, aspartate, and arginine in a rapidly hydrolyzed short-peptide form. Under this framing, any biological effect could reflect substrate delivery for protein synthesis, arginine-related nitric-oxide/endothelial effects (arginine is the substrate for nitric oxide synthase), aspartate-mediated Krebs-cycle anaplerosis, or non-specific stress-protective effects common to amino-acid mixtures. If correct, equivalent amino-acid provision — for example L-citrulline 3–6 g daily, which raises arginine with better pharmacokinetics — could produce similar effects at lower cost.
No G-protein-coupled receptor, nuclear receptor, or defined enzyme target has been identified for Cardiogen. It does not bind beta-adrenoceptors, angiotensin II receptors, or aldosterone receptors, and does not inhibit ACE, renin, or neprilysin. This absence of a defined pharmacological target is characteristic of the Khavinson framework and distinguishes Cardiogen from evidence-graded cardiac drugs, whose mechanisms are mapped at the receptor and structural-biology level.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Applies only to synthetic lyophilized AEDR peptide (typically 5 mg or 10 mg vials), not the commercial 20 mg oral capsule. Warm the vial to room temperature, then add bacteriostatic water down the glass wall and allow passive dissolution over 5–10 minutes. A common target is a 5 mg vial in 2 mL BAC water = 2.5 mg/mL (0.25 mg per 10 units on a U100 insulin syringe), giving 0.8 mL for a 2 mg dose and 1.0 mL for a 2.5 mg dose. An alternative is 5 mg in 3 mL = 1.67 mg/mL. Store reconstituted solution refrigerated at 2–8 C (not frozen); stability is about 28–30 days. Discard if cloudy, discolored, or containing particulate.
Beginner (oral)
- Dose
- 1 capsule (20 mg nominal; historically 2–4 mg actual AEDR)
- Frequency
- Once daily
- Timing
- Sublingual or oral on empty stomach, 30–45 min before breakfast; hold sublingually ~60 seconds
- Duration
- 10 consecutive days, then stop
- Route
- Oral / sublingual
Use a vendor with third-party HPLC and a certificate of analysis. 60-day washout before repeating. Track baseline BP, resting HR, energy, and exertional tolerance. Continue all existing cardiac medications. Expect only mild subjective effects.
Intermediate
- Dose
- 20 mg oral/sublingual daily OR 2–5 mg subcutaneous daily
- Frequency
- Once daily
- Timing
- Oral on empty stomach, or SC with site rotation
- Duration
- 10 consecutive days per cycle
- Route
- Oral / sublingual or subcutaneous
Cycle twice yearly (autumn and spring typical). Space Cardiogen cycles from other Khavinson peptides by at least 2 months. Monitor home BP twice daily and resting HR during cycles; annual echocardiogram/ECG if baseline cardiac disease. Notify cardiology of bioregulator use.
Advanced (Khavinson rotation)
- Dose
- 20 mg oral/sublingual OR 5 mg SC daily
- Frequency
- Once daily during a 10-day window
- Timing
- Month 1 days 1–10; repeat Month 10 days 1–10, interleaved with Epitalon (Month 4) and Pinealon (Month 7)
- Duration
- 10-day cycles within a 12-month rotation, 2–3 month washouts between
- Route
- Oral / sublingual or subcutaneous
For users with 6+ months of Khavinson bioregulator experience, stable cardiac status, and close cardiology coordination. Layer on top of evidence-graded cardiac care (BP control, LDL reduction, antiplatelets, SGLT2/GLP-1 where indicated, exercise). Baseline and annual echocardiogram, 24-hour ambulatory BP, and ECG. Stop and reassess if any cycle produces new cardiovascular symptoms.
- SC administration bypasses first-pass hydrolysis and delivers higher theoretical systemic exposure per mg than oral capsules.
- The 20 mg oral capsule contains an undisclosed amount of actual AEDR (historically 2–4 mg, the balance excipients).
- The 10-on / 60-off cycling pattern is uniform across Khavinson peptides; no dose-ranging or duration-comparison study establishes it as optimal.
- Russian clinicians favor autumn entry before winter cardiovascular-stress season, but this timing is convention, not empirically optimized.
- Do not exceed 20 mg oral or 5 mg SC per day; there is no established maximum and continuous (non-cycled) dosing has not been characterized for safety.
- Avoid in significant renal impairment (eGFR <30) and decompensated hepatic disease pending modern pharmacokinetic data.
- Discontinue cycles at least 2 weeks before planned cardiac procedures and do not use perioperatively without explicit cardiology approval.
- Cardiogen is not a substitute for guideline-directed cardiac therapy; continue all prescribed medications through any cycle.
Evidence
Research & clinical studies (4)
Peptide bioregulator biodistribution (tritiated-peptide uptake in rodent tissues)
Tritium-labeled Khavinson peptides showed tissue uptake across heart, liver, brain, thymus, and kidney within minutes of intraperitoneal or oral administration, though the label did not distinguish intact peptide from hydrolysis products.
In vitro cardiomyocyte culture effects of AEDR
Cultured cardiomyocytes exposed to AEDR showed morphological preservation and improved contractility markers in models of oxidative stress and simulated ischemia.
Khavinson short-peptide bioregulator cardiac research
Rodent cardiac-injury model work and mechanistic discussion supporting the proposed cardiomyocyte-survival and regeneration framework for cardiac bioregulator peptides.
Peptide bioregulators and aging (observational context)
Uncontrolled observational data in elderly patients with chronic cardiovascular disease reported subjective improvement and modest echocardiographic changes after bioregulator cycles.
Combinations
Stacking & blends
Khavinson cardiovascular rotation
Year-long tissue-targeted bioregulator rotation for cardiovascular and general aging
Cardiogen (cardiac) is rotated with Epitalon (pineal/general) and Pinealon (brain/cerebrovascular) in 10-day cycles spaced by 2–3 month washouts, layered on top of evidence-graded cardiac care.
Cardiogen + Vesugen
Combined cardiac and vascular bioregulation
Listed as synergistic in interaction data — the cardiac tetrapeptide paired with the vascular tripeptide to address both myocardium and endothelium.
Cardiovascular supplement adjunct stack
Layer cardiac-support supplements alongside a Cardiogen cycle
CoQ10 (mitochondrial electron transport), L-citrulline (arginine/NO pathway), omega-3 (anti-inflammatory), taurine (membrane stabilization), and berberine (lipid/glucose metabolism) are compatible from an interaction standpoint, though none have been tested for synergy with Cardiogen.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy (no reproductive toxicology data)
- Breastfeeding (no excretion/infant safety data)
- Pediatric use (no safety data)
- Recent MI or stroke within 3 months (acute recovery period)
- Active acute coronary syndrome
- Decompensated heart failure
- High-grade AV block
- Severe aortic stenosis
- Active/perioperative cardiac surgery
- Severe renal impairment (eGFR <30)
- Decompensated hepatic disease
The reported short-term safety profile is mild, with no serious adverse cardiac events in the published Russian literature at convention dosing. However, total documented human exposure is small (low thousands), modern pharmacovigilance does not exist, and long-term safety over years of cycles is uncharacterized. Use only third-party HPLC-verified product with endotoxin testing, and coordinate with cardiology if you have cardiovascular disease. Do not stop guideline-directed cardiac medications to test Cardiogen alone.
FAQ
Cardiogen — common questions
What is Cardiogen and what is it claimed to do?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, AEDR) developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology as a myocardial bioregulator. It is claimed to support cardiomyocyte function, vascular endothelium, and cardiac tissue resilience in aging, ischemic-injury recovery, and chronic heart failure. Russian literature reports in vitro cardiomyocyte effects, rodent cardiac-injury data, and small uncontrolled observational series. It is not FDA- or EMA-approved and is best treated as an experimental bioregulator, not an established cardiac therapy.
Does Cardiogen actually help with heart disease?
The evidence is thin. Russian uncontrolled observational series report subjective improvements and modest echocardiographic changes in elderly patients, but no placebo-controlled RCTs and no hard-endpoint trials (MACE, cardiovascular death, heart failure hospitalization) exist. For any cardiovascular condition, evidence-graded therapy — blood pressure control, LDL reduction, SGLT2 inhibitors in heart failure, antiplatelets in ASCVD, and aerobic exercise — is the foundation. Cardiogen is not a substitute.
What is the typical Cardiogen dose?
The Khavinson convention is a 20 mg oral/sublingual capsule once daily for 10 consecutive days with 60–90 day washouts. The 20 mg capsule contains an undisclosed actual AEDR content (historically 2–4 mg). For subcutaneous use with synthetic lyophilized peptide, 2–5 mg daily for 10 days is the community pattern. No dose-ranging trial establishes that these amounts are optimal — they are convention.
Is Cardiogen safe?
Reported short-term safety is mild — occasional nausea, mild headache, rare rash, and injection-site reactions with SC use — with no serious adverse cardiac events in published Russian literature at convention dosing. However, documented human exposure is small, modern pharmacovigilance does not exist, and long-term safety is uncharacterized. Absolute contraindications include pregnancy, breastfeeding, pediatric use, active ACS, decompensated heart failure, and high-grade AV block.
Can I use Cardiogen with my existing cardiac medications?
No documented pharmacokinetic interactions exist between Cardiogen and beta-blockers, ACE inhibitors, ARBs, statins, antiplatelets, anticoagulants, SGLT2 inhibitors, or GLP-1 agonists, and interactions are considered unlikely given rapid peptide hydrolysis. However, no formal interaction studies have been done. For narrow-therapeutic-index drugs (digoxin, antiarrhythmics, warfarin), get cardiology approval first, and continue all prescribed therapy through any cycle.
How does Cardiogen compare to other Khavinson peptides?
Cardiogen occupies the cardiac-specific niche within the Khavinson family, sibling to Pinealon (brain), Thymogen (immune), Vilon (thymus), Livagen (liver), Bronchogen (respiratory), and Epitalon (pineal/general). They share the passive-membrane-permeation-plus-chromatin-modulation mechanistic claim. Cardiogen has less published literature than Epitalon or Thymogen, with core Russian evidence focused on cardiac indications.
Why does vendor verification matter for Cardiogen?
Cardiogen (Ala-Glu-Asp-Arg) shares three of four amino acids with Cartalax (Ala-Glu-Asp) and Epithalon (Ala-Glu-Asp-Gly), so mass-spectrometry identity confirmation is essential to verify the correct sequence, alongside independent HPLC purity testing. In a cardiovascular context, mislabeled or contaminated peptide is particularly concerning.
Is Cardiogen legal?
Cardiogen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. No active FDA approval pathway exists for it.
